Elena A. Poluektova

Elena A. Poluektova

Auto-generated profile, based on publicly available information

Elena A. Poluektova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2020 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
VSV. I. Simanenkov
V. I. Simanenkov
IMIgor V. Maev
Igor V. Maev
OTO. N. Tkacheva
O. N. Tkacheva
SAS. A. Alekseenko
S. A. Alekseenko
DADmitrii Nikolaevich Andreev
Dmitrii Nikolaevich Andreev
ЮКЮ. В. Котовская
Ю. В. Котовская
Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус

2 January 2022 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
VIVladimir Ivashkin
Vladimir Ivashkin
IMI. V. Maev
I. V. Maev
YSYu. A. Shelygin
Yu. A. Shelygin
EBE. K. Baranskaya
E. K. Baranskaya
SBS. S. Belous
S. S. Belous
Vladislav Vladimirovich TsukanovVladislav Vladimirovich Tsukanov
Vladislav Vladimirovich Tsukanov
Aim. Current clinical recommendations accentuate current methods for the diagnosis and treatment of irritable bowel syndrome (IBS).Key points.IBS is a functional bowel disorder manifested with recurrent, at least weekly, abdominal pain with the following attributes (any two leastwise): link to defecation, its frequency or stool shape. The symptoms are expected to persist for at minimum three months in a total six-month follow-up. Similar to other functional gastrointestinal (GI) disorders, IBS can be diagnosed basing on the patient symptoms compliance with Rome IV criteria, provided the absence of potentially symptom-causative organic GI diseases. Due to challenging differential diagnosis, IBS can be appropriately established per exclusionem, with pre-examination as follows: general and biochemical blood tests; tissue transglutaminase IgA/IgG antibody tests; thyroid hormones test; faecal occult blood test; hydrogen glucose/ lactulose breath test for bacterial overgrowth; stool test for enteric bacterial pathogens and Clostridium difficile A/B toxins; stool calprotectin test; abdominal ultrasound; OGDS, with biopsy as appropriate; colonoscopy with biopsy. The IBS sequence is typically wavelike, with alternating remissions and exacerbations often triggered by psychoemotional stress. Treatment of IBS patients includes dietary and lifestyle adjustments, various-class drug agents prescription and psychotherapeutic measures.Conclusion. Adherence to clinical recommendations can facilitate timely diagnosis and improve medical aid quality in patients with different clinical IBS variants.

30 December 2022 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
VIVladimir Ivashkin
Vladimir Ivashkin
TLT. L. Lapina
T. L. Lapina
IMIgor V. Maev
Igor V. Maev
ODO. M. Drapkina
O. M. Drapkina
Roman KozlovRoman Kozlov
Roman Kozlov
Vladislav Vladimirovich TsukanovVladislav Vladimirovich Tsukanov
Vladislav Vladimirovich Tsukanov
Aim: bring to the attention of practitioners indications for anti-Helicobacter therapy, methods and procedure for diagnostics and eradication therapy ofН. pyloriinfection.Key points. Chronic gastritis caused byН. pyloriinfection, including asymptomatic persons, may be considered as an indication for eradication therapy of Н. pylori as etiological therapy and opportunistic screening for gastric cancer prevention. Indications, for obligatory anti-Helicobacter therapy include peptic ulcer, gastric MALT lymphoma, early gastric cancer (EGC) with endoscopic resection. H. pylori primary diagnostics methods include13C-urea breath test,H. pyloristool antigen lab test, rapid urease test and serological method. The serological method cannot be used after anti-Helicobacter therapy.In RussiaH. pyloristrains' resistance to clarithromycin does not exceed 15 % in most regional studies. The first line therapy forН. pyloriinfection eradication is the standard triple therapy including a proton pump inhibitor (PPI), clarithromycin and amoxicillin, enhanced with bismuthate tripotassium dicitrate. A classic four-component therapy based on bismuthate tripotassium dicitrate or quadrotherapy without bismuth drug products which includes PPI, amoxicillin, clarithromycin and metronidazole, may be used as alternative to the first line eradication therapy. The standard triple therapy may be prescribed for 14 days only in those regions, where it has been proven to be effective. Quadrotherapy with bismuthate tripotassium dicitrate is also used as main second line therapy in case of standard triple therapy, bismuth enhanced standard triple therapy or combined therapy failure. Another second line therapy includes PPI, levofloxacin and amoxicillin, to which a bismuth-containing drug product may be added. The third line therapy is selected individually based on previously used treatment settings.Conclusion. In each case ofH. pyloriinfection the decision for eradication therapy should be made, which is especially relevant as eradication ofH. pylorihas been recognized as an effective measure for the prevention of gastric cancer.

27 September 2021 in World Journal of Hepatology
Verified
Journal Article
Open access
RMRoman Maslennikov
Roman Maslennikov
VIVladimir Ivashkin
Vladimir Ivashkin
IEIrina Efremova
Irina Efremova
EPElena Poluektova
Elena Poluektova
ESElena Shirokova
Elena Shirokova
Probiotics in hepatology: An update

5 December 2024 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
VIVladimir Ivashkin
Vladimir Ivashkin
ATA. S. Trukhmanov
A. S. Trukhmanov
IMIgor V. Maev
Igor V. Maev
ODOxana M. Drapkina
Oxana M. Drapkina
Maria LivzanMaria Livzan
Maria Livzan
ЮУЮ. П. Успенский
Ю. П. Успенский
Aim. These recommendations are developed for practitioners in order to familiarize them with modern diagnostic methods, management features and pharmacotherapy of patients with gastroesophageal reflux disease (GERD).General provisions. GERD is the most common reason for patients to visit clinics. There are esophageal and extraesophageal manifestations of GERD. Patients' complaints of heartburn and regurgitation remain the most sensitive and specific clinical manifestations of GERD. The diagnosis of GERD is established on the basis of anamnestic data, instrumental examination (detection of reflux esophagitis during upper gastrointestinal endoscopy, detection of pathological gastroesophageal reflux with 24-hour pH-metry or/and 24-hour pH-impedance monitoring). Patients with suspected GERD and the absence of erosive and ulcerative changes in the mucous membrane of the esophagus or the presence of erosive esophagitis of Grade A according to Los Angeles Classification of Gastroesophageal Reflux Disease are recommended to conduct 24-hour pH-metry on PPI off to exclude or confirm the diagnosis of GERD. Patients with extraesophageal manifestations of GERD without classic symptoms (heartburn, regurgitation) are recommended to undergo 24-hour pH-impedance monitoring with discontinuation of proton pump inhibitor therapy. When deciding on surgical treatment, all patients need to perform high-resolution esophageal manometry and 24-hour pH-impedance monitoring. Complications of GERD include bleeding, strictures, Barrett’s esophagus and esophageal adenocarcinoma. The main groups of medications used in the treatment of GERD are proton pump inhibitors (PPIs), potassium-competitive acid blockers (P-CABs), alginates, antacids, and prokinetics. PPIs are the drugs of choice in the treatment of both symptoms of gastroesophageal reflux disease and existing erosive esophagitis. Combination therapy Rebamipide with PPIs increases the effectiveness of relief of GERD symptoms, as well as reduces the frequency of relapses.Conclusion. These clinical recommendations will improve the quality of medical care for patients with GERD.

2 June 2021 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
VIVladimir Ivashkin
Vladimir Ivashkin
IMIgor V. Maev
Igor V. Maev
DAD. I. Abdulganieva
D. I. Abdulganieva
SAS. A. Alekseenko
S. A. Alekseenko
AGA. V. Gorelov
A. V. Gorelov
ЮУЮ. П. Успенский
Ю. П. Успенский
Aim.The practical guidelines are intended for primary care physicians, general practitioners, paediatricians, gastroenterologists and general internists to advance the treatment and prevention of gastroenterological diseases in adults and children in therapies with probiotics, prebiotics, synbiotics and their enriched functional foods.Key points.Probiotics are live microorganisms that sustain health of the host when supplied in adequate amounts. Prebiotics include human-indigestible but accessible to gut microbiota substances expediting specific changes in the composition and/or activity of gastrointestinal microbiota that favour the host health. The mechanism of probiotic action comprises the quorum resistance maintenance, nutrient substrate metabolism and end metabolite recycling, macroorganism-sustaining substrate production, as well as the mediation of local and adaptive immune responses.The Russian Federation regulates market differently for biologically active food additives (BAFA), medicinal products (drugs) and functional food products (FFP). We overview the probiotic strains regulated in Russia as BAFAs, drugs and FFPs and provide recommendations on the use of these strains in treatment and prevention of gastroenterological diseases in children and adults.Conclusion.The clinical efficacy of probiotics, prebiotics, synbiotics and fortified functional foods depends on the prebiotic and strain properties and is verified in appropriate comparative clinical trials. Not all probiotics registered in Russia as BAFAs, drugs and FFPs have a strain identity, which provides no warranty of the clinical effect expected. The FFP legislation demands improved regulation mechanisms and control for therapeutic efficacy.